HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "sell" rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $75.00 price objective on the biotechnology company's stock. HC Wainwright's price target indicates a potential downside of 37.15% from the stock's previous close.

Other analysts have also issued research reports about the company. Needham & Company LLC reissued a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday. Evercore ISI reduced their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a "buy" rating and a $165.00 price target on the stock. Finally, Guggenheim boosted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $178.71.

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded up $0.50 during trading on Wednesday, reaching $119.33. The company's stock had a trading volume of 659,197 shares, compared to its average volume of 799,497. Sarepta Therapeutics has a one year low of $102.15 and a one year high of $173.25. The stock has a market capitalization of $11.40 billion, a PE ratio of 95.46 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a fifty day moving average of $121.92 and a 200 day moving average of $130.13.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares in the company, valued at $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares of the company's stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SRPT. CIBC Asset Management Inc increased its holdings in shares of Sarepta Therapeutics by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company's stock valued at $339,000 after purchasing an additional 86 shares in the last quarter. EP Wealth Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 2.1% during the 2nd quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company's stock worth $774,000 after acquiring an additional 103 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 3.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company's stock worth $557,000 after acquiring an additional 145 shares during the period. Nisa Investment Advisors LLC raised its holdings in Sarepta Therapeutics by 16.9% during the third quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company's stock worth $134,000 after purchasing an additional 155 shares during the last quarter. Finally, Huntington National Bank grew its holdings in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.